Are zongertinib and zonertinib the same and analysis of differences in pharmacological effects and clinical applications

Zongertinib (Zongertinib) and Zongertinib are actually the same drug in terms of pharmacology and clinical application, but have different names, which may be due to differences in different regions or literature translation. The essential ingredients and mechanisms of action of the two are completely the same, so the names can be used interchangeably in clinical practice. However, it should be noted that in specific prescriptions or drug registration information, the locally approved trade name or generic name should be used to avoid confusion.

Zongatinib/Zongatinib is an oral tyrosine kinase inhibitor (TKI), mainly targeted at patients with RET fusion or mutation-positive tumors. Its mechanism of action is by inhibiting RETtyrosine kinase activity and blocking the downstream MAPK and PI3K-AKT signaling pathways, thereby inhibiting tumor cell proliferation, promoting apoptosis, and blocking tumor angiogenesis. This precise targeting property enables it to show good anti-tumor activity in a variety of solid tumors such as RET driven non-small cell lung cancer (NSCLC).

In terms of clinical application, Zongatinib/ Zongatinib has shown significant efficacy in multiple clinical trials. For example, in patients with RETfusion-positive advanced NSCLC, the drug can significantly extend progression-free survival (< span>PFS) and improve the objective response rate (ORR); at the same time, it also provides an effective treatment option for patients who cannot tolerate traditional chemotherapy or who have failed multiple treatments. Due to its oral administration and precise targeting, patients have high compliance and can significantly improve their quality of life.

Although zongatinib/Zovitinib has significant efficacy, but its adverse reactions and monitoring requirements still need to be paid attention to. Common adverse reactions include hypertension, abnormal liver function, diarrhea and rash, and some patients may develop cardiovascular or liver and kidney function-related problems. Therefore, blood pressure, liver and kidney function and electrolyte levels should be regularly monitored during use, and the dose should be adjusted or supportive treatment should be taken according to clinical conditions. Generally speaking, zongatinib and zongatinib are the same drug, and their pharmacological effects, indications and clinical applications are exactly the same. The key lies in name selection and usage management.

Reference materials:https://www.drugs.com/